Sirolimus(Tavanta)

N/A

Report date: 2026/03/04 20:01:44

Base Information

Drug NameSirolimus(Tavanta)
Drug Alias NameDRGT18-2
ClassificationSmall molecules > Heterocyclic drugsSmall molecules > Molecular Glue
Mechanisms of ActionmTOR Complex 2 inhibitorsMammalian target of Rapamycin (mTORC1) inhibitors
TargetsmTOR Complex 2Mammalian target of Rapamycin (mTORC1)
Therapy Area/IndicationsRejection of organ transplantation
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesTavanta Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesTavanta Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsRejection of organ transplantation
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A